Overview

Addressing Dementia Via Agitation-Centered Evaluation

Status:
Completed
Trial end date:
2020-04-17
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, double-blind, placebo-controlled study, to assess the efficacy and safety of AXS-05 in the treatment of agitation in patients with Alzheimer's disease.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Axsome Therapeutics, Inc.
Treatments:
Bupropion